SNSE SCHEDULE 13G: SEC filing
Filed with the SEC on · accession 0001493152-26-052839
SNSE filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 17, 2026. Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai filed a Schedule 13G reporting beneficial ownership of 1,385,878 shares, or 5.4%, of Faeth Therapeutics, Inc. common stock as of November 9, 2026.
Summary of the filing
Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai filed a Schedule 13G reporting beneficial ownership of 1,385,878 shares, or 5.4%, of Faeth Therapeutics, Inc. common stock as of November 9, 2026. The filing is a passive investment disclosure under Rule 13d-1(c), with no intent to influence control of the issuer.
Key details
✦ Ask GOAX AI about this filing — what it means for SNSE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SNSE?
Click hereFrequently asked questions
What did SNSE file with the SEC on Nov 17, 2026?
SNSE filed a SCHEDULE 13G (SEC filing). Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai filed a Schedule 13G reporting beneficial ownership of 1,385,878 shares, or 5.4%, of Faeth Therapeutics, Inc. common stock as of November 9, 2026. The filing is a passive investment disclosure under Rule 13d-1(c), with no intent to influence control of the issuer.
How do I read a SCHEDULE 13G?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).
Other SNSE SEC filings
- SCHEDULE 13G · SEC filingNov 16, 2026
- SCHEDULE 13G/A · SEC filingNov 13, 2026
- 8-K · SEC filingNov 9, 2026
- 8-K · Fda approvalNov 9, 2026
- 10-Q · SEC filingNov 3, 2026
- 8-K · SEC filingNov 3, 2026
- 8-K · Board changeOct 27, 2026
- 8-K · Board changeSep 17, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
Get alerts when SNSE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days